http://www.eiffeltechnologies.com.au
Eiffel Technologies Ltd, is a bioengineering company focused on improving the performance and delivery of pharmaceuticals, proteins and peptides. Based in Melbourne, Australia, the company is dedicated to the development and commercialization of SCF drug technologies to improve therapeutic outcomes and patient administration of new and currently marketed pharmaceuticals. Eiffel Technologies Ltd has international collaborations with Sheffield Pharmaceuticals Inc, Amarin Corporation Plc, Profile Therapeutics Plc and BattellePharma Inc.
Solstice Neurosciences, Inc. ("Solstice") is a specialty biopharmaceutical company focused on the development, manufacture, sales and marketing of specialty biopharmaceutical products. Solstice and its employees are committed to adopting the highest ethical standards in their dealings with patients, physicians and the community-at-large. As such, Solstice has developed a Comprehensive Compliance Program ("CCP") in accordance with the "Compliance Program Guidance for Pharmaceutical Manufacturers," published by the Office of the Inspector General, U.S. Department of Health and Human Services ( "OIG Guidance"). Our Compliance Program, established by our Board of Directors in conjunction with Solstice senior management, is a central component of our commitment to the highest standards of corporate conduct.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has been involved in the development of injectable collagenase (XIAFLEX) for multiple indications. The indications are for the treatment of Dupuytren’s disease, Peyronie’s disease and frozen shoulder. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for XIAFLEX. Under this agreement, BioSpecifics Technologies has granted Auxilium a worldwide license to develop products containing XIAFLEX and the option to develop and license the technology for use in additional indications other than dermal formulations labeled for topical administration, including cellulite and lipomas. XIAFLEX is in a Phase III trial for treatment of Dupuytren’s disease. (Source: 10KSB)
Cangene Corporation (Cangene) is a Canada-based biopharmaceutical company. The Company is engaged in the business of developing, manufacturing, and commercializing products and technologies for global markets. The business segments of the Company are biopharmaceutical operations and contract services. The two types of products of the Company includes hyperimmunes, which are concentrated specialty antibody preparations made from plasma, and recombinant biopharmaceuticals, which are therapeutic proteins made by introducing a particular gene into a host organism, which in turn produces the protein of interest. Its hyperimmune products include VariZIG (varicella zoster immune globulin), VIG (vaccinia immune globulin) and HepaGam B (hepatitis B immune globulin). Its recombinant biopharmaceutical products include Leucotropin and Accretropin. (Source: ARS)
Amersham is a world leader in medical diagnostics and in life sciences. Headquartered in the UK, the company had annual sales of £1.62 billion in 2002 and around 10,000 employees worldwide. Its strategy is to build its position as a leading provider of products and technologies enabling disease to be better understood, diagnosed earlier and treated more effectively.
Bioniche Life Sciences Inc. is a Canadian biopharmaceutical company engaged in the research, development, manufacturing and commercialization of human and animal health products and technologies worldwide. Headquartered in Belleville, Ontario, the Company has offices and manufacturing facilities in Canada, the United States, Europe, and Australia. The Company has three business units: Human Health, Animal Health, and Food Safety. The Human Health business unit is responsible for research, discovery and clinical development of human health products. The Animal Health business unit is responsible for the research, development, manufacturing and marketing of animal health products worldwide. The Food Safety business unit is responsible for research, development, manufacturing and marketing of biopharmaceutical animal health products to help prevent disease in humans and improve the safety of food and water supplies worldwide. (Source: ARS)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory